New Impact Factor of 1.785 for Current Oncology! We are pleased to announce that Current Oncology’s 2014 Impact Factor has increased to 1.785! This i

 
CO-NEWSLETTER-LOGO withdate
ASCO-Vancouver-2015-image FORAbovePubisherIntro
***

New Impact Factor of 1.785 for Current Oncology!

We are pleased to announce that Current Oncology’s 2014 Impact Factor has increased to 1.785! This is an increase from our 2013 stats, where we received an impact factor of 1.643.

Our 2014 Impact Factor is a significant achievement for the journal, and demonstrates the increased recognition of Current Oncology in the field, and the improved relevance and quality of our articles. Thank you to our team of Editors and Section Editors, Reviewers and Authors for your valuable contribution to the journal. We look forward to continued success in 2015 as the journal continues to strengthen and grow!

We hope you will consider Current Oncology when submitting your manuscripts for publication. We encourage submissions from all fields of cancer medicine. For information about article submission, please visit our “Information for Authors” page.

logo70

Multimed Inc.
Publisher of Current Oncology
www.multi-med.com

***
ImpactFactor2014
***
InPress-CON
***
LookingAhead-CON

Upcoming in Current Oncology

The future table of contents for Current Oncology, Volume 22, Number 4 (August 2015) is now available. For the most up-to-date listing of scheduled papers, please visit the following link:
http://www.current-oncology.com/index.php/oncology/about/futureTOC

***
EditorSpotlight
Olson photo

Karin Olson, RN, PhD
Editor of our Nursing Section (since 2011)

Dr. Olson completed a B. Sc. in Nursing at the University of Alberta (1976), a Masters in Health Science with a focus in Health Promotion at the University of Toronto (1981), and a PhD in Educational Psychology at the University of Alberta (1990). She is a Professor in the Faculty of Nursing at the University of Alberta where she is also a Distinguished Scholar at the International Institute for Qualitative Methodology. Dr. Olson also holds an adjunct appointment to the Division of Palliative Medicine, Faculty of Medicine and Dentistry, University of Alberta. Her research focuses on use of qualitative and quantitative methods to develop an etiological model of fatigue in advanced cancer.

***
HaveYouHeard-CON

Health Canada Approves Treatment ZYDELIG (idelalisib) For Incurable Blood Cancers

Health Canada has approved a new treatment option for relapsed patients with chronic lymphocytic leukemia (CLL) and for follicular lymphoma (FL). Gilead Sciences Canada’s ZYDELIG™ (idelalisib) tablets, received a Notice of Compliance in combination with rituximab for the treatment of patients with relapsed CLL. ZYDELIG also received a Notice of Compliance with Conditions as a stand-alone treatment for patients with FL who have undergone at least two prior systemic regimens and are resistant to both rituximab and an alkylating agent.

CLL and FL are slow-growing incurable blood cancers, most common in adults 50 years of age and older, that can lead to life-threatening complications such as anemia, serious infection and bone marrow failure requiring treatment. As conventional chemotherapy is not curative for CLL or FL, nearly all patients will eventually relapse after their initial treatment. At relapse, patients often face fewer treatment options because they may be unable to tolerate chemotherapy, or become resistant to treatment.

“Idelalisib offers an important treatment option for Canadians living with CLL and FL at the time of relapse,” said Dr. Carolyn Owen, Assistant Professor, Division of Hematology and Hematological Malignancies, Foothills Medical Centre, Calgary. “With these cancers, relapsed patients are often unable to tolerate traditional chemotherapy and thus, they require new active treatment options, particularly if several other therapies have failed. Many of these patients have previously had limited, if any, treatment options. We are now entering a new era of management of CLL and FL patients. In the pivotal CLL clinical study, idelalisib demonstrated a statistically significant improvement in progression-free survival.”

ZYDELIG is an oral inhibitor of phosphoinositide 3-kinase (PI3K) delta, a protein that plays a role in the activation, proliferation and viability of B cells, a critical component of the immune system. PI3K delta signaling is active in many B-cell leukemias and lymphomas. By inhibiting the protein this blocks several cellular signaling pathways that drive B-cell viability.


No Author Fees for Clinical Research and Clinical Trial Articles

560x100 Banner

Current Oncology is seeking high-quality original clinical research and clinical trial articles. Areas may include research related to treatment, prevention, diagnostic, screening, and quality of life. Articles submitted should contain information that is relevant directly to clinical oncology practice, and have clear potential for application to the current or future practice of cancer medicine.

To help encourage submissions, Current Oncology will waive Standard Author Fees for all original clinical research and clinical trial articles, submitted between July 1st and December 31st, 2015.

View our full announcement for more details.


NewDesign

New Look For Current Oncology

The June 2015 issue premiers the new design of the journal’s article format. Highlights of the new design include:
• Easy access to citation information for articles
• Abstract & corresponding author prominent on 1st page
• Reduced font - allowing for publication of more articles in both print & online format
• Introduction of shading for easier reading and interpretation of tables

We hope our readers enjoy Current Oncology’s new look!

***
ReadersChoice-COn

Have you had the chance to view these Current Oncology “Most-Read” articles?

Most Read Articles in PubMed Central (May 2015)

Legalizing euthanasia or assisted suicide: the illusion of safeguards and controls
Pereira J.
Curr Oncol. 2011 Apr;18(2):e38-45

Management of arthralgias associated with aromatase inhibitor therapy
Thorne C.
Curr Oncol. 2007 Dec;14 Suppl 1:S11-9

Prophylaxis and management of acute radiation-induced skin reactions: a systematic review of the literature
Salvo N, Barnes E, van Draanen J, Stacey E, Mitera G, Breen D, Giotis A, Czarnota G, Pang J, De Angelis C.
Curr Oncol. 2010 Aug;17(4):94-112

Most Read Recently* Published Articles at www.current-oncology.com

Evidence-based guidance on venous thromboembolism in patients with solid tumours
Shea-Budgell MA, Wu CM, Easaw JC.
Curr Oncol. 2014 Jun;21(3):e504-14. doi: 10.3747/co.21.1938

Patients' perceptions of gene expression profiling in breast cancer treatment decisions
Bombard Y, Rozmovits L, Trudeau ME, Leighl NB, Deal K, Marshall DA
Curr Oncol. 2014 Apr;21(2):e203-11. doi: 10.3747/co.21.1524

A Canadian consensus on the management of newly diagnosed and relapsed acute promyelocytic leukemia in adults
Seftel MD, Barnett MJ, Couban S, Leber B, Storring J, Assaily W, Fuerth B, Christofides A, Schuh AC.
Curr Oncol. 2014 Oct;21(5):234-50. doi: 10.3747/co.21.2183

*Published within past 12 months

***
CO-NEWS-MEETINGALERT
ASCO-Vancouver Multi-Med undermeeting

OncologyEducation.com is pleased to present the Best of ASCO Conference in Vancouver on July 10th, 2015!

This is a program licensed by the American Society of Clinical Oncology. The focus of this event will be to provide medical oncologists and other healthcare practitioners in Canada with a summary of the most significant treatment advances presented at the ASCO 2015 Annual Meeting, with presentations focused on several key disease sites.

Click here for more information.

ESMO Miami Multi-Med undermeeting

OncologyEducation.com is pleased to present The ESMO Summit Americas: Oncology Updates — From Evidence to Practice, an official ESMO® Summit Meeting, Nov. 6-8TH, Miami, Florida.

This program is licensed by the European Society for Medical Oncology. This international meeting will highlight the most significant, practice-changing data to emerge from the European Society of Medical Oncology's Annual Conference (ESMO 2015) and put it into context for an anticipated audience of more than 200 oncology professionals from across the Americas.

The ESMO Summit Americas is a three-day event with presentations focused on several key disease sites. As part of the conference, several panel-type symposia will also be organized, with focus on integrating the evidence into clinical practice for key tumour sites and to address regional differences in practice and patient management guidelines.

Click here for more information.

***
300 x 80px-01
JenCampisano

The Cancer / Parenthood Polarity

This new mom writes about the challenges of being a mom living with cancer…watching her son become a little boy, and hoping she’ll be lucky enough to see him become a man.

***
QuickLinks-CON
***

Contact Us

Email-CON
 
Address-CON
 
Phone-CON
 
Web-CON
twitter
1px